Human Embryonic-Derived Mesenchymal Progenitor Cells (hES-MP Cells) are Fully Supported in Culture with Human Platelet Lysates

Bioengineering
S. M. Jonsdottir-BuchOlafur Eysteinn Sigurjonsson

Abstract

Human embryonic stem cell-derived mesenchymal progenitor (hES-MP) cells are mesenchymal-like cells, derived from human embryonic stem cells without the aid of feeder cells. They have been suggested as a potential alternative to mesenchymal stromal cells (MSCs) in regenerative medicine due to their mesenchymal-like proliferation and differentiation characteristics. Cells and cell products intended for regenerative medicine in humans should be derived, expanded and differentiated using conditions free of animal-derived products to minimize risk of animal-transmitted disease and immune reactions to foreign proteins. Human platelets are rich in growth factors needed for cell culture and have been used successfully as an animal serum replacement for MSC expansion and differentiation. In this study, we compared the proliferation of hES-MP cells and MSCs; the hES-MP cell growth was sustained for longer than that of MSCs. Growth factors, gene expression, and surface marker expression in hES-MP cells cultured with either human platelet lysate (hPL) or fetal bovine serum (FBS) supplementation were compared, along with differentiation to osteogenic and chondrogenic lineages. Despite some differences between hES-MP cells grown in hPL- and ...Continue Reading

References

Nov 25, 2003·Biology of Reproduction·M AmitJ Itskovitz-Eldor
May 18, 2004·Experimental Hematology·Elisabeth H JavazonAlan W Flake
Jun 15, 2004·Journal of Translational Medicine·Ester Fonsatti, Michele Maio
Jun 9, 2005·Nature Biotechnology·Lisa M Hoffman, Melissa K Carpenter
Apr 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nikolaos A DallasLee M Ellis
Apr 5, 2008·International Immunopharmacology·Jelka GabrilovacBarbara Cupić
Jun 12, 2009·Stem Cell Research·Camilla KarlssonRaimund Strehl
Sep 29, 2009·Biomaterials·Nathalie ChevallierHelene Rouard
May 28, 2010·Stem Cells·Elodie Bachelard-CascalesVéronique Maguer-Satta
Jun 24, 2010·Bone·Toshio Matsumoto, Masahiro Abe
Dec 21, 2010·TheScientificWorldJournal·Eduardo Pérez-GómezMiguel Quintanilla
Jan 21, 2011·European Cells & Materials·Andrea AugelloCosimo De Bari
Feb 1, 2011·Tissue Engineering. Part a·William GruenlohJan A Nolta
Jun 4, 2011·PloS One·Christian NiehageBernard Hoflack
Oct 6, 2011·Biochemical and Biophysical Research Communications·Nóra VargaAgota Apáti
Nov 23, 2011·Biomarkers in Medicine·Nataša Todorović-RakovićDragica Nikolić-Vukosavljević
Dec 22, 2012·Respiration; International Review of Thoracic Diseases·George Kolios, Yuben Moodley
Jan 15, 2013·Differentiation; Research in Biological Diversity·V B Fernández ValloneN A Chasseing
May 28, 2013·Lancet·Lorna M Williamson, Dana V Devine
Feb 11, 2014·BioMed Research International·Chiho Ikebe, Ken Suzuki
Sep 20, 2015·Methods : a Companion to Methods in Enzymology·Stephen M RichardsonAli Mobasheri

❮ Previous
Next ❯

Citations

Aug 6, 2020·Bioengineering·Joaquim M S CabralMaria Margarida Diogo

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
flow cytometry
PCR

Software Mentioned

Cellquest Pro
GraphPad ® Prism
REST
Excel
GraphPad
- 384 ©

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.